Koninklijke Philips N.V. Q4 FY25 Results — Earnings Call Analysis
Published 29 May 2026 | Health Care Equipment and Supplies | Market Cap: ₹25.2K Cr
- Philips expects continued strength and sustained momentum in North America with double-digit order growth, driven by both strong and expanding hospitals (pg. - Philips expects continued sales growth with a full-year comparable sales growth outlook of 1% to 3% for 2025.
From Koninklijke Philips N.V.'s Q4 FY25 earnings-call transcript · updated 29 May 2026.
Price
₹26.45
Market Cap
₹25.2K Cr
P/E Ratio
23.2
Revenue Rank
Margin Rank
How does Koninklijke Philips N.V. rank in Health Care Equipment and Supplies?
Compare Koninklijke Philips N.V. against every Health Care Equipment and Supplies company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →Philips expects continued strength and sustained momentum in North America with double-digit order growth, driven by both strong and expanding hospitals (pg. 15).
- →Overall group comparable sales growth guidance is maintained at 1% to 3% for the full year 2025, with Q4 expected to show sequential improvement (pgs. 5, 13, 15).
- →Connected Care expected to grow within the 1%-3% sales range, Personal Health to grow slightly above mid-single-digit range, and Diagnosis & Treatment (D&T) to deliver slight year-over-year growth (pg. 5).
- →SKU reduction (Project Synchronized) and innovation are expected to continue supporting margin improvements and sales growth in 2026 and beyond (pg. 14).
- →Growth businesses are being driven for both margin expansion and top-line growth, with innovation launches like radiation therapy suites and AWS cloud partnerships anticipated to support growth (pgs. 7, 13, 14).
- →China market remains cautious near-term but positive long term; hospital demand in North America remains strong but unevenly spread (pg. 3).
📈 Profitability & Margins
Rank 3- →Philips expects continued sales growth with a full-year comparable sales growth outlook of 1% to 3% for 2025.
- →Adjusted EBITA margin is anticipated at the upper end of the 11.3% to 11.8% range for 2025, reflecting confidence in execution.
- →Adjusted diluted EPS from continuous operations increased by 3% year-over-year to EUR 0.36 in Q3 2025.
- →The company aims for strong cash delivery and margin expansion alongside growth, aiming to set up for a good 2026.
- →Productivity improvements and innovation-driven gross margin expansion are key margin drivers.
- →Pricing opportunities exist but are balanced to not impede growth.
- →No expected commercial impact from the FDA warning letter, and separate remediation efforts are ongoing.
- →Continued investments in North America and strategic partnerships support sustained momentum.
- →The company plans to share more detailed future growth plans at their Capital Markets Day in February 2026.
🏗️ Capital Expenditure Plans
Yes- →Philips announced a EUR 150 million investment in the U.S. to expand production and strengthen cost efficiency and local supply continuity, particularly in Ultrasound and wider facilities (Page 7).
- →Further medium-term initiatives include supplier network enhancements and manufacturing location optimization to mitigate tariff impacts (Page 4 & 7).
- →Commitment to manufacturing footprint strengthening in the U.S. as part of reshoring efforts (Page 7).
- →Philips continues disciplined investment in innovation, including launches like the CT 5300 and radiation therapy suite supporting margin and growth (Pages 4 & 7).
- →Capital Markets Day in February 2026 will detail evolution of the 3-year plan focusing on consistent value creation and value acceleration (Page 5).
💰 Fundraising & Capital Structure
No information- →The document does not mention any current or planned new fundraising through debt or equity.
- →Philips ended Q3 2025 with approximately EUR 1.9 billion in cash and around EUR 6.5 billion in net debt.
- →The company maintains a disciplined focus on managing leverage, with a net debt to adjusted EBITA ratio of 2.2x.
- →Philips remains committed to maintaining a strong investment grade credit rating.
- →No announcements or guidance indicate plans for issuing new debt or equity in the near future.
- →The focus appears to be on executing existing financial strategies, improving margins, and delivering on growth commitments through operational performance rather than raising new capital.
📋 Order Book & Pipeline
Yes- →Q3 reported 8% order intake growth, predominantly driven by Connected Care (CC).
- →Strong order performance in Connected Care driven by hospital patient monitoring and partnerships.
- →Diagnostic & Treatment (D&T) orders were strong in Q2 and expected to further step up in Q4.
- →Order intake is expected to be positive in Q4, with a more even distribution between CC and D&T.
- →Enterprise Informatics (EI) order intake improved strongly in Q3, but conversion from orders to sales is slow due to long cycles.
- →Overall, the company maintains a strong order funnel and positive order momentum into Q4 and 2026.
- →No major inventory restocking seen; order books reflect real demand growth.
- →Emphasis on continued strong order intake across segments for the full year and into next year.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Frequently Asked Questions
What were Koninklijke Philips N.V. Q4 FY25 results?
- Philips expects continued strength and sustained momentum in North America with double-digit order growth, driven by both strong and expanding hospitals (pg. - Philips expects continued sales growth with a full-year comparable sales growth outlook of 1% to 3% for 2025.
What is Koninklijke Philips N.V. share price analysis?
Koninklijke Philips N.V. currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of $25,162. Investors should review the full earnings analysis for detailed insights.
Is Koninklijke Philips N.V. planning capital expenditure?
- Philips announced a EUR 150 million investment in the U.S.
Keep Koninklijke Philips N.V. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.